Core Viewpoint - The company announced that its subsidiary, Gansu Puan Pharmaceutical Co., Ltd., has successfully completed the renewal process for its Drug Production License, which was approved by the Gansu Provincial Drug Administration on September 25, 2025. The renewal is primarily due to the application for the reduction of the commissioned production of the cough syrup (National Medicine Standard Z20050288) and is not expected to have a significant impact on production and operations [1]. Summary by Categories - Company Update - Gansu Puan Pharmaceutical Co., Ltd. has received a renewed Drug Production License from the Gansu Provincial Drug Administration [1]. - The renewal process was completed on September 25, 2025 [1]. - Operational Impact - The change in the Drug Production License is related to the application for the reduction of commissioned production of a specific cough syrup [1]. - The company has completed the necessary legal procedures for this change, which is not anticipated to significantly affect its production and operations [1].
陇神戎发:控股子公司取得换发后的《药品生产许可证》